Arzneimittelbedingte Agranulozytosen

Gross, R; Hellriegel, K. P.

doi:10.1007/bf01013880

Cited by 7 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously also widely used as analgesics and anti-inflam-reported (12,15) that patients with these sympmatory agents. Sudden agranulocytosis appear-toms do not form a homogeneous population, ing sporadically in a patient receiving pyra-but can be clearly divided into two groups with zolone drugs has been extensively studied (3,6, possibly different pathogenesis. Here we pre -7).…”

mentioning

confidence: 99%

Idiosyncrasy to Pyrazolone Drugs

Czerniawska-Mysik¹,

Szczeklik²

1981

Allergy

View full text Add to dashboard Cite

Studies carried out in 68 patients with idiosyncratic reactions to noramidopyrine and/or aminophenazone led to distinction of two different groups. In the first group: 1) noramidopyrine, aminophenazone, phenylbutazone and sulfinpyrazone as well as several other inhibitors of cyclooxygenase, including aspirin, precipitated bronchoconstriction; 2) skin tests with pyrazolone drugs were virtually negative; 3) all patients had chronic asthma. In the second group: 1) noramidopyrine and aminophenazone induced anaphylactic shock and/or urticaria; 2) skin tests with these drugs were highly positive; 3) phenylbutazone, sulfinpyrazone and several other cyclooxygenase inhibitors, including aspirin, could be taken with impunity; 4) chronic bronchial asthma was present in only one-fourth of the patients. We suggest that the pathogenic mechanisms responsible for the idiosyncratic reactions involve inhibition of cyclooxygenase in the first group, and allergic reactions in the second group. Distinction of these two groups is of clinical importance since in individual patients it gives insight into the safe administration of pyrazolone and aspirin-like drugs.

show abstract

mentioning

confidence: 99%